The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

Pharmacogenomics Journal

Volumn 1, Issue 3, 2001, Pages 204-210

  Kerb, R ^a   Aynacioglu, A S ^b,c   Brockmoller J ^b   Schlagenhaufer, R ^a   Bauer, S ^b   Szekeres, T ^d   Hamwi, A ^d   Fritzer Szekeres, M ^d   Baumgartner, C ^e   Ongen H Z ^f   Guzelbey P ^f   Roots, I ^b   Brinkmann, U ^a  

^a Epidauros Biotechnologie AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PAMUKKALE UNIVERSITY   (Turkey)

^d UNIVERSITY OF VIENNA   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Pharmacogenetlcs; Polymorphism; TDM

Indexed keywords

ANTICONVULSIVE AGENT; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; MIXED FUNCTION OXIDASE; PHENYTOIN; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; DRUG MONITORING; FEMALE; GENE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; FEMALE; GENES, MDR; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENYTOIN; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035752933     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500025     Document Type: Article

References (5)

1. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-622.
2. Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Coldstein JA et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Blochem Pharmacol 1999; 57: 1297-1303.
3. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Blochem I 1993; 289: 533-538.
4. De Morals SM, Wilkinson GR, Blaisdell J, Meyer DA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
5. De Morals SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans./Bio! Chem 1994; 269:15419-15422.